| abstract |
The present invention is directed to aspartic protease inhibitors represented by the following structural formula: n nor a pharmaceutically acceptable salt thereof.n n The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I). n Methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using these aspartic protease inhibitors are also disclosed. |